Skip to main content
. 2020 Dec 25;23:743–756. doi: 10.1016/j.omtn.2020.12.015

Figure 7.

Figure 7

PPARγ inhibition promotes muscle atrophy in vivo

(A) Gastrocnemius muscle morphology and weight in sh-scramble- and PPARγ shRNA-treated mice. Scale bar: 1 cm. n = 6. (B) The grip strength of right hindlimb in sh-scramble- and PPARγ shRNA-treated mice. n = 5, 6. (C) WGA staining was performed to quantify muscle fiber CSA from sh-scramble- and PPARγ shRNA-treated mice. Scale bar: 20 μm. n = 6 per group. (D) Quantitative real-time PCR analysis of Atrogin-1 and Murf-1 expression in sh-scramble- and PPARγ shRNA-treated mice. n = 5, 6. (E) TUNEL staining was performed to quantify apoptosis from sh-scramble- and PPARγ shRNA-treated mice. Scale bar: 50 μm. n = 4 per group. (F) Western blot analysis for the ratio Bax/Bcl2 and Cleaved-caspase3/Caspase3 from sh-scramble- and PPARγ shRNA-treated mice. n = 3 per group. (G) Western blot analysis for LC3II, P62 and ubiquitin protein expression in sh-scramble- and PPARγ shRNA-treated mice. n = 3 per group. (H) Quantitative real-time PCR analysis the ratio of mtDNA/genomicDNA in sh-scramble- and PPARγ shRNA-treated mice. n = 5 per group. (I) Quantitative real-time PCR analysis of miR-29b expression in sh-scramble- and PPARγ shRNA-treated mice. n = 6 per group. Data are shown as mean ± SD. ∗p < 0.05. ∗∗p < 0.01. See also Figure S7.